Natco Pharma gets EIR from USFDA for Kothur facility
New Delhi: Drug firm Natco Pharma on Friday said it has received establishment inspection report (EIR) from the US health regulator for its Kothur facility in Telangana after successful completion of inspection.
Natco Pharma announces successful EIR from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug manufacturing facility in Kothur village in Mahabubnagar district during January 16 24, 2017, the company said in a BSE filing on Thursday.
"The Kothur facility predominantly caters to regulated international markets, including USA," it added.
EIR is given to an establishment after completion of inspection by the USFDA.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd